Ocugen Outlines Clinical Milestones for OCU400 and Targets Three BLA Submissions by 2028
During the Q3 2026 earnings call, Ocugen (OCGN) management provided a strategic roadmap focused on advancing its late-stage modifier gene therapy programs. A key milestone includes the anticipated release of top-line Phase III data for OCU400, which is expected in the first quarter of 2027. The company aims to submit three Biologics License Applications (BLAs) by 2028. To support these long-term commercial goals, Ocugen has begun establishing a presence in Europe to facilitate pre-commercial activities and global expansion.
Tickers: $OCGN
Topics: European Expansion Gene Therapy Phase III Clinical Trials Quarterly Results